Guggenheim Capital’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Guggenheim Capital’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-81,971	Closed	-$8M	–	3158
2015 Q1	$8M	Buy	81,971 +18,123	+28%	+$1.92M	0.02%	950
2014 Q4	$5.92M	Sell	63,848 -1,700	-3%	-$134K	0.01%	1045
2014 Q3	$4.51M	Buy	65,548 +12,206	+23%	+$874K	0.01%	1251
2014 Q2	$5.59M	Sell	53,342 -7,331	-12%	-$624K	0.01%	1118
2014 Q1	$5.03M	Sell	60,673 -1,934	-3%	-$179K	0.01%	1120
2013 Q4	$4.05M	Buy	+62,607	New	+$3.72M	0.01%	1223

Guggenheim Capital's GEVA Position: Q2 2015 in Review

Guggenheim Capital sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 81,971 shares — an estimated $8M sold.

Guggenheim Capital first reported a position in GEVA in Q4 2013 and held it in 6 quarters. The position peaked at $8M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Guggenheim Capital reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Guggenheim Capital sold 81,971 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $8M.
Guggenheim Capital first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q4 2013 and held it in 6 quarters.
Guggenheim Capital's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $8M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Guggenheim Capital's 13F filing for Q2 2015, filed 14 Aug 2015.